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hypermethylation in NSCLCs (36%), which was particu-
larly evident in squamous cell carcinomas (p = 0.024) 
and in the tumours with moderate-to-good differen-
tiation (p = 0.01). Transcript level of COL1A1, as well 
as PRPF40A and UCP2, exhibited striking association 
(p ≤ 0.001) with the expression of hypoxia markers. In 
addition, we demonstrate in lung cancer cell lines exposed 
to hypoxia or oxidative stress that COL1A1 transcription 
significantly responds to oxygen depletion, while other 
genes showed the modest upregulation in stress conditions.
Conclusion In conclusion, our data revealed that 
COL1A1, UCP2, and PRPF40A are novel players impli-
cated in the complex network of hypoxia response in 
NSCLC.
Keywords COL1A1 · PRPF40A · UCP2 · Hypoxia · 
Non-small cell lung cancer
Introduction
Lung cancer is among the most prevalent neoplastic dis-
eases accounting for the highest mortality in both genders 
worldwide (Boisvert et al. 2010). Due to typically asympto-
matic early stage and late diagnosis, lung tumours are diffi-
cult to treat as the therapeutic options become limited. The 
reduction of lung cancer mortality has been set as a major 
priority in the UK through the development of more effi-
cient early diagnosis and intervention tools, both of which 
require better understanding of the molecular biology of 
the disease (Lung et al. 2000).
Our previous studies suggested cytoglobin (CYGB) as a 
putative tumour suppressor gene in lung (Xinarianos et al. 
2006) and oesophageal (McRonald et  al. 2006) tumours 
and successive in vitro and in vivo studies provided further 
Abstract 
Purpose Collagen 1A1 (COL1A1), RNA-binding and 
pre-mRNA Processing Factor (PRPF40A), and Uncoupling 
Protein 2 (UCP2) were identified as downstream effectors 
of cytoglobin (CYGB), which was shown implicated in 
tumour biology. Although these three genes have been pre-
viously associated with cancer, little is known about their 
status in lung malignancies.
Methods Hereby, we investigated the expression and pro-
moter methylation of COL1A1, PRPF40A, and UCP2 in 
156 non-small cell lung cancer (NSCLC) and adjacent nor-
mal tissues.
Results We demonstrate that COL1A1 and PRPF40A 
mRNAs are significantly overexpressed in NSCLC 
(p < 1 × 10−4), while UCP2 exhibits a trend of upregu-
lation (p = 0.066). Only COL1A1 promoter revealed 
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evidence in support of this hypothesis (Oleksiewicz et  al. 
2013; Shivapurkar et  al. 2008; Thuy le et  al. 2011). Nev-
ertheless, CYGB was also associated with hypoxia and 
cancer aggressiveness (Fang et al. 2011; Oleksiewicz et al. 
2013). Shivapurkar and co-workers identified three down-
stream effector genes of CYGB, which were downregulated 
in CYGB-overexpressing lung and breast cancer cell lines 
(Shivapurkar et al. 2008). These genes were: collagen 1A1 
(COL1A1), RNA-binding and pre-mRNA Processing Fac-
tor (PRPF40A) and Uncoupling Protein 2 (UCP2). Inter-
estingly, COL1A1, PRPF40A, and UCP2 expression was 
linked to the metabolic pathways implicated in hypoxia and 
oxidative stress (Baffy 2010; Falanga et  al. 2002; García-
Trevijano et al. 1999; Papaiahgari et al. 2007), events asso-
ciated with more aggressive and therapy-resistant tumours 
(Harris 2002; Landriscina et al. 2009).
COL1A1 is an extracellular matrix protein, whose over-
expression was linked to breast (Jansen et  al. 2005), gas-
tric (Yasui et al. 2005), and colorectal tumours (Steinman 
2012). UCP2 is a mitochondrial membrane protein trans-
porting protons from the intermembrane space to mito-
chondrial matrix (i.e., uncoupling). Upregulation of UCP2 
was reported in colon cancer (Horimoto et al. 2004), hepa-
tocellular cancer, and cholangiocarcinoma (Baffy 2010). 
Finally, PRPF40A participates in assembly of splicing 
machinery onto the pre-mRNAs (Lin et al. 2004). Little is 
known about the involvement of PRPF40A in cancer. How-
ever, its upregulation was reported in pancreatic cancer 
(Thakur et al. 2008) and in the cells harbouring various p53 
cancer-related mutations (Randolph et al. 1999).
In previous microarray analyses, COL1A1 (Ramaswamy 
et al. 2003) and UCP2 (Ayyasamy et al. 2011) were found 
upregulated in various malignant tissues, including lung 
cancer. However, no single-gene validation of these results 
in lung cancer has been presented so far. Thus, we aimed to 
explore UCP2, PRPF40A and COL1A1 mRNA expression, 
and promoter methylation to determine their molecular pro-
file in NSCLC and their association to clinicopathological 
parameters and hypoxia markers.
Materials and methods
Tissue collection
NSCLC and adjacent normal tissues were collected from 
156 patients operated between 1995 and 2005 at the Liv-
erpool Heart and Chest Hospital, UK. All patients sub-
mitted informed consent, and the study was approved by 
the local ethics committee. The patient group [described 
in (Oleksiewicz et  al. 2011)] represents typical cohort 
with resectable lung tumour as decided following stand-
ard diagnostic procedures (Table 1). All tumour samples 
come from the patients that did not receive any prior 
chemo- or radio-therapy. The patient cohort consisted 
of 99 males and 57 females, with the mean age 65.7 
(range 40–87). This set contained two most frequent his-
tological subtypes: squamous cell lung cancer (SqCLC) 
(N = 86) and adenocarcinoma (N = 70). With regard to the 
pathological stage, tumours were split into the follow-
ing groups: T1 (N = 11), T2 (N = 125), T3 (N = 15), and 
T4 (N = 5), while according to differentiation status, the 
group breakdown was: poor (N = 48) and moderate/good 
(N = 107). Nodal metastasis occurred in 75 cases, while 
80 patients had metastasis-free nodes. The follow-up 
data included 12 alive and 57 dead patients. The tumour 
samples were snap frozen and grossly micro-dissected to 
ascertain more than 80% tumour tissue. The normal adja-
cent tissue was resected at least 5  cm from the tumour 
mass. All the methylation and expression values were 
included in the analysis, even in the absence of normal, 
methylation, or expression counterpart data for the given 
patient. Overall, we utilised RNA from 128 normal and 
146 NSCLC tissues and DNA from 26 normal and 91 
NSCLC tissues.
Cell lines
Adenocarcinoma (H358) and SqCLC (CALU1) lung can-
cer cell lines (ATCC) were maintained at 37 °C/5%  CO2 in 
DMEM/F-12/Glutamax™-I (Invitrogen) with 10% FBS. 
For hypoxic studies, the cells were cultured at 1%  O2 for 
48h, while oxidative stress was achieved with 300 µM  H2O2 
treatment for 24 h.  H2O2 concentration was chosen as an 
IC50 of CALU1 and H358 according to our survival curve.
Promoter methylation
DNA extraction, bisulfite conversion, and pyrosequenc-
ing analyses were performed as described (Oleksie-
wicz et  al. 2011). PCR reactions were performed with 
 HotStarTaq®Plus Mastermix (Qiagen) according to manu-
facturer’s protocol with 85  ng bisulfite-converted DNA 
and 0.16 µM primers. The following PCR primers (MWG 
Operon) were used: COL1A1_F GGA GAG AAG GTA AAT 
GGA AG, COL1A1_R-biotinylated AAC CTA ACC CCA 
ACC CTA , PRPF40A_F GAG TAG AGA ATA GAG AGG 
ATTTG, PRPF40A_R-biotinylated TAA TCA AAA CCC 
AAA AAA C, UCP2_F-biotinylated GTT TTG GGA TTG 
ATT GTT , and UCP2_R CAA AAC TAA AAC CAA ACT 
CAC. For pyrosequencing reaction, 0.33  µM sequencing 
primer was used: COL1A1_S (GAG AAG GTA AAT GGA 
AGA ), PRPF40A_S (ATA GAG AGG ATT TGGA), and 
UCP2_S (AAA CTA AAA CCA AACTC).
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Gene expression
RNA isolation, reverse transcription, qPCR, and data anal-
ysis were previously described (Oleksiewicz et  al. 2011). 
The following primer/probe mixes were used in the qPCRs: 
COL1A1 (Hs01076780_g1), PRPF40A (Hs00215465_m1), 
and UCP2 (Hs01075225_m1) (Life Technologies).
GSH-Glow™ glutathione assay
Cellular level of glutathione was measured with the GSH-
Glow™ glutathione assay (Promega) on Genios plate 
reader (Tecan) according to manufacturer’s instructions. 
The luminescence values were normalised to the total pro-
tein level as assessed with the DC Biorad Assay (Biorad).
Statistical analysis
Non-parametric tests were used for statistical analyses 
(PASW Statistics 18.0, SPSS) as 1-sample Kolmogo-
rov–Smirnov test showed skewed distribution of continu-
ous variables. Pairwise comparisons between normal and 
NSCLC samples were performed with Wilcoxon test. The 
differences for continuous variables among independent 
cohorts within clinical parameters were determined with 
the Kruskal–Wallis and Mann–Whitney tests. Bivariate 
correlation was probed with Spearman’s test. Bonferroni 
correction was applied to adjust for multiple comparisons. 
Patients’ survival was calculated with the log rank test.
Results
Gene expression analysis of COL1A1, PRPF40A, 
and UCP2 in NSCLC
Our comparative qPCR analysis showed abun-
dant COL1A1 overexpression in tumours (median 
RQ = 975.4, IQR 389.9–3172.7, N = 132) when com-
pared to adjacent normal tissues (69.4, 29.8–235.6, 
N = 119, Mann–Whitney test, p < 1 × 10−4) (Fig.  1a). 
Similarly, PRPF40A was overexpressed in NSCLC sam-
ples (RQ = 3.49, 1.13–11.84, N = 135 vs 1.53, 0.98–3.16, 
N = 119, Mann–Whitney test, p < 1 × 10−4) (Fig.  1b). 
In the case of UCP2, there was only a trend of higher 
expression observed in lung tumours (RQ = 0.043, 
0.025–0.08, N = 136 vs 0.034, 0.026–0.055, N = 122, 
Mann–Whitney test, p = 0.066) (Fig.  1c). UCP2 
mRNA expression was higher in lung adenocarcino-
mas (RQ = 0.053, 0.03–0.087, N = 61) than in SqCLCs 
(RQ = 0.035, 0.019–0.072, N = 75, Mann–Whitney test, 
p = 0.015). Apart from that no other associations were 
Table 1  Clinicopathological 
data available for the analysed 
NSCLC population
Clinical parameters Data for all patients 
(N = 156)
Data for methylation 
analysis (N = 91)




 SqCCL 86 (55%) 56 (62%) 15 (58%)
 AdenoCa 70 (45%) 35 (38%) 11 (42%)
Differentiation
 Poor 48 (31%) 26 (29%) 8 (31%)
 Moderate to good 107 (69%) 65 (71%) 18 (69%)
Tumour stage
 T1 11 (7%) 4 (4%) 2 (8%)
 T2 125 (80%) 74 (81%) 21 (81%)
 T3 15 (10%) 9 (10%) 2 (8%)
 T4 5 (3%) 4 (4%) 1 (4%)
Nodal status
 Negative 75 (48%) 44 (49%) 17 (65%)
 Positive 80 (52%) 46 (51%) 9 (35%)
Gender
 Male 99 (63%) 62 (68%) 19 (73%)
 Female 57 (37%) 29 (32%) 7 (27%)
Follow-up
 Alive 12 (17%) 9 (18%) 5 (28%)
 Dead 57 (83%) 40 (82%) 19 (73%)
Age
 Mean age (range) 66 (40–87) 66 (40–87) 64 (40–87)
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observed between COL1A1, PRPF40A or UCP2 mRNA 
expression and patients’ gender, age, survival, smoking 
history, TNM classification, and tumour histology and 
differentiation.
Promoter methylation analysis of COL1A1, PRPF40A, 
and UCP2 in NSCLC
For the promoter methylation analysis, we set the 
hypermethylation threshold according to the previ-
ously described method (Normal reference range = mean 
MtI + 2 × standard deviation of the normal samples) 
(Oleksiewicz et  al. 2011) at MtI = 19.9% for UCP2 
and MtI = 13.0% for COL1A1. PRPF40A promoter 
was unmethylated in all samples tested. UCP2 pro-
moter hypermethylation was observed only in 5/91 
NSCLC samples and none (0/26) of the normal tissues. 
We noted elevated COL1A1 promoter methylation in 
33/91 NSCLCs (Fig.  1D) and in 2/26 normal samples. 
Although the difference in methylation between grouped 
normal and tumour samples was insignificant, pairwise 
comparison showed significant hypermethylation of 
COL1A1 promoter in NSCLC (p = 0.035, Wilcoxon test, 
N = 26 pairs). The samples selected for the latter analy-
sis featured clinicopathological profile representative 
of all tumour samples utilised in this study (Table  1), 
so that the pairwise comparison was not confounded 
by the  clinical factors. Furthermore, higher methyla-
tion was observed in SqCLCs (median MtI = 8.72%, 
IQR 1.95–26.18, N = 56) than in adenocarcinomas 
(2.28, 1.36–5.5, N = 35, Mann–Whitney test, p = 0.024, 
Fig. 1e), as well as in the moderately and well-differen-
tiated tumours (MtI = 5.19%, IQR 1.99–28.21, N = 65) 
in comparison with poorly differentiated NSCLCs (2.18, 
1.39–5.45, N = 26, Mann–Whitney test, p = 0.01, Fig. 1f). 
Apart from that observation COL1A1 methylation did 
not correlate with patients’ gender, age, survival, smok-
ing history, and TNM classification. Moreover, methyla-
tion was not associated with the mRNA expression val-
ues, even when potentially confounding factors (histology 
and differentiation) were taken into account.
COL1A1, PRPF40A, and UCP2 expression correlates 
with hypoxia markers
Next, we evaluated interrelationships between COL1A1, 
PRPF40A, UCP2, and hypoxia markers (CYGB, Hypoxia-
Inducible Factor 1α—HIF1α and Vascular Endothelial 
Growth Factor—VEGFa), whose expression profiles were 
previously reported (Oleksiewicz et  al. 2011). PRPF40A 
exhibited the strongest hypoxia association pattern among 
all genes under investigation (Table  2; Fig.  2a–c). Its 
mRNA expression level correlated with CYGB (ρ = 0.795, 
p < 1 × 10−4, N = 130), HIF1α (ρ = 0.841, p < 1 × 10−4, 
N = 129), and VEGFa (ρ = 0.677, p < 1 × 10−4, N = 95). 
The hypoxia dependence was observed as well in the case 
of COL1A1 (Fig.  2d–f), whose expression was associ-
ated with CYGB (ρ = 0.709, p < 1 × 10−4, N = 124), HIF1α 
(ρ = 0.646, p < 1 × 10−4, N = 127) and, to a lesser extent, 
with VEGFa (ρ = 0.356, p = 5.8 × 10−4, N = 90). Similar 
relationships were seen in the case of UCP2 (UCP2 vs 
CYGB: ρ = 0.495, p < 1 × 10−4, N = 129, UCP2 vs HIF1α: 
ρ = 0.559, p < 1 × 10−4, N = 130 and vs VEGFa: ρ = 0.343, 
p = 7.1 × 10−4, N = 94, Fig.  2g–i). The expression profiles 
of COL1A1, PRPF40A, and UCP2 genes correlated with 
each other. The strongest positive association was observed 
between PRPF40A and COL1A1 (ρ = 0.612, p < 1 × 10−4, 
N = 129), PRPF40A and UCP2 (ρ = 0.596, p < 1 × 10−4, 
N = 132), while the weakest between COL1A1 and UCP2 
(ρ = 0.353, p < 1 × 10−4, N = 128).
COL1A1, PRPF40A, and UCP2 expression under stress 
conditions in vitro
Hypoxia response is activated not only with oxygen deple-
tion, but also with nutrient deficiency, oxidative stress, and 
other signalling pathways. Therefore, we wanted to assess 
whether COL1A1, PRPF40A, and UCP2 might be regu-
lated by hypoxia and/or oxidative stress in  vitro. Cellular 
response to oxidative and hypoxic stress was confirmed by 
testing glutathione content (Fig. 3a) and the mRNA expres-
sion of VEGFa (Fig.  3b), respectively. COL1A1 became 
upregulated in hypoxic conditions in both cell lines; how-
ever, this was significant only in CALU1 (RQ = 3.15 ± 0.8 
vs 1.0 ± 0.07 in normoxic cells, p = 0.02, Mann–Whitney), 
but not in H358 (RQ = 2.2 ± 0.7 vs 1.1 ± 0.06, p = 0.074). 
PRPF40A and UCP2 expression little changed at 1%  O2, 
as only CALU1 exhibited modest upregulation of UCP2 
(RQ = 1.5 ± 0.24 vs 0.9 ± 0.15, p = 0.04, Mann–Whitney). 
Similarly, oxidative stress did not evoke significant changes 
in the expression of COL1A1, UCP2, and PRPF40A genes. 
This lack of responsiveness to stress conditions was not 
caused by CpG methylation, as the promoters of COL1A1, 
UCP2, and PRPF40A showed low methylation level 
(MtI < 10%) in both cell lines (Fig. 3f).
Fig. 1  Boxplot representation of a COL1A1, b PRPF40A, and c 
UCP2 mRNA levels in NSCLC and normal tissues. d COL1A1 pro-
moter methylation profile in NSCLC and normal samples, e in adeno-
carcinomas and SqCLCs, and f in the tumours with poor and mod-
erate-to-good differentiation. A number of cases analysed with the 
Mann–Whitney (a–c, e, f) or Wilcoxon (d) test and corresponding p 
values are provided. Representative pyrograms of COL1A1 promoter 
for normal (g) and NSCLC (h) samples. X-axis indicates nucleotide 
dispensation order, while Y-axis luminescence intensity for each 
incorporated nucleotide. Boxes above the graphs show the percentage 
of methylated cytosines for each CpG site
◂
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Discussion
Although UCP2, PRPF40A, and COL1A1 upregula-
tion has been previously observed in malignant tissues 
(Ayyasamy et al. 2011; Ramaswamy et al. 2003; Thakur 
et al. 2008) and associated with response to hypoxia and 
oxidative stress (Baffy 2010; Falanga et al. 2002; García-
Trevijano et  al. 1999; Papaiahgari et  al. 2007), little is 
known about their status in lung cancer. The data pre-
sented hereby demonstrate a trend of overexpression of 
UCP2 and significant overexpression of COL1A1 and 
PRPF40A in NSCLCs compared to adjacent normal 
Table 2  Association between mRNA expression of COL1A1, PRPF40A, UCP2, CYGB, HIF1α, and VEGFa assessed with Spearman’s test
Rho values (correlation coefficient), p values, and the number of samples for each analysis are provided
PRPF40A UCP2 CYGB HIF1α VEGFa
COL1A1 Rho = 0.612 
p < 1 × 10−4
N = 129
Rho = 0.353
p < 1 × 10−4
N = 128
Rho = 0.709 p < 1 × 10−4
N = 124
Rho = 0.646
p < 1 × 10−4
N = 127
Rho = 0.356 p = 5.8 × 10−4
N = 90
PRPF40A Rho = 0.596
p < 1 × 10−4
N = 132
Rho = 0.795 p < 1 × 10−4
N = 130
Rho = 0.841
p < 1 × 10−4
N = 129
Rho = 0.677
p < 1 × 10−4
N = 95
UCP2 Rho = 0.495 p < 1 × 10−4
N = 129
Rho = 0.559
p < 1 × 10−4
N = 130





Fig. 2  Scatterplots representing correlations between mRNA expres-
sion of PRPF40A (a–c), COL1A1 (d–f), UCP2 (g–i), and hypoxia 
markers: CYGB (a, d, g), HIF1α (b, e, h), or VEGFa (c, f, i) in 
NSCLC resected tissues. The p and rho values and numbers of paired 
samples included in the Spearman’s correlation test are indicated on 
each graph
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tissues. Moreover, expression of all three genes corre-
lated with that of hypoxia markers: CYGB, HIF1α, and 
VEGFa. Furthermore, we observed that PRPF40A pro-
moter remained unmethylated, while UCP2 promoter was 
sporadically methylated in few cancer samples. Interest-
ingly, we demonstrated a trend of increased methyla-
tion within COL1A1 promoter in a subset of NSCLCs; 
however, it did not associated with COL1A1 expression. 
This might be due to insufficient sample number taken 
into analysis, existence of another promoter control-
ling COL1A1 expression or presence of a potent factor 
that affects COL1A1 mRNA content more profoundly 
than DNA methylation, e.g., tumour hypoxia. Indeed, 
COL1A1 expression strongly correlates with hypoxia 
markers in tissues and becomes upregulated as well 
in low oxygen tension in our cell line model. Thus, the 
effect of hypoxia may be masking the methylation events 
observed in the subset of the NSCLC tissues. Surpris-
ingly, our data indicate positive correlation of COL1A1, 
UCP2, and PRPF40A with CYGB expression, which has 
been previously shown to be inverse in in  vitro experi-
ments (Shivapurkar et  al. 2008). In the data published 
by Shivapurkar et  al., transient CYGB overexpression 
resulted in >twofold downregulation of the three genes; 
however, this effect was less pronounced and reproduc-
ible in the cells with stable CYGB overexpression. While 
in vivo data not always recapitulate in vitro observations, 
prolonged tumour hypoxia identified in our tissue set may 
additionally modify the interdependence of CYGB and its 
proposed downstream effectors. For example, in tumour 
microenvironment, CYGB may undergo functional altera-
tions that affect its properties as the regulator of down-
stream genes.
Despite the clustering of the three genes with hypoxia 
markers in tissues, in  vitro hypoxia had differential effect 
on their expression. The statistical correlation between 
various genes might reflect similar, but unrelated expres-
sion patterns. These patterns could manifest the specific-
ity of pathologic transcriptome rather than the activation 
of a particular signalling pathway. From this point of view, 
lack of responsiveness in the cells incubated at low  O2 
level may indicate independence of PRPF40A and UCP2 
from hypoxia in NSCLCs. It is possible as well that in the 
lung cancer setting, UCP2 and PRPF40A act upstream of 
hypoxia pathways, thus inducing expression of HIF1α inde-
pendently of the  O2 tension. Alternatively, the expression 
of PRPF40A and UCP2 may require additional stimulators, 
which are present in tumour microenvironment in vivo, but 
absent in vitro (e.g., more acute  O2 deficit, cytokine release, 
and interactions with extracellular stroma) (Creighton et al. 
2005). Falanga and colleagues, for instance, reported that 
in dermal fibroblasts, hypoxia augments the transcription 
and extracellular deposition of COL1A1 via TGF-b path-
way (Falanga et  al. 2002). Although the three genes have 
been previously shown upregulated upon hypoxic stimu-
lus at the mRNA and/or protein level (Deng et  al. 2012; 
Falanga et al. 2002; Lai et al. 2016), observations in other 
experimental settings suggest their hypoxia-driven down-
regulation (Duval et al. 2016; Perry et al. 2013; Wang et al. 
2016). Altogether these data indicate that the responsive-
ness to low  O2 level by COL1A1, UCP2, and PRPF40A is 
dependent on cellular context.
While UCP2 overexpression might contribute to 
Warburg effect and promote tumourigenic phenotype 
(Ayyasamy et  al. 2011), the implications of deregulated 
expression patterns of PRPF40A and COL1A1 remain to 
be elucidated. It is likely, however, that these genes may 
assist in the adaptive responses to oxidative stress and 
hypoxia/reoxygenation events, thus promoting tumour 
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Fig. 3  Glutathione (GSH) level normalised to total protein content 
a in CALU1 and H358 cell lines after 24h incubation with 300 µM 
 H2O2 (N = 6). Relative mRNA expression of b VEGFa, c COL1A1, 
d PRPF40A, and e UCP2 in CALU1 and H358 cell lines after 48h 
incubation at 1%  O2 (h) or 24 h incubation with 300 µM  H2O2 (o). 
Bars represent mean (N = 4) RQ values (±SEM) calibrated against 
untreated (N) control cells. *p < 0.05 (Mann–Whitney test). Pyrose-
quencing analysis of CpG sites within COL1A1 (N = 6 CpG sites), 
PRPF40A (N = 7), and UCP2 (N = 5) promoters in CALU1 and H358 
(f). The bars represent mean methylation index (MtI ± SEM of CpG 
sites)
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aggressiveness, metastasis, and treatment resistance. As 
these issues are pertinent to cancer patient management, it 
would of interest to investigate this hypothesis in the future.
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